Difference between revisions of "Pegfilgrastim-bmez (Ziextenzo)"
(Created page with "==General information== Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF), biosimilar of pegfilgrastim. Binds to cell surface receptors on hemat...") |
Warner-admin (talk | contribs) m (Text replacement - "‚" to ",") |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF), biosimilar of pegfilgrastim. Binds to cell surface receptors on hematopoietic cells and stimulates | + | Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF), biosimilar of pegfilgrastim. Binds to cell surface receptors on hematopoietic cells and stimulates proliferation, differentiation, and some end-cell functional activation. |
<br>Route: SC | <br>Route: SC | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 9: | Line 9: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *11 | + | *2019-11-05: Approved |
==Also known as== | ==Also known as== | ||
| − | |||
*'''Brand names:''' Ziextenzo | *'''Brand names:''' Ziextenzo | ||
Revision as of 17:53, 1 August 2023
General information
Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF), biosimilar of pegfilgrastim. Binds to cell surface receptors on hematopoietic cells and stimulates proliferation, differentiation, and some end-cell functional activation.
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Patient drug information
History of changes in FDA indication
- 2019-11-05: Approved
Also known as
- Brand names: Ziextenzo